Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

June 23rd 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

Feasibility Results Support Launching Full Phase III PART Trial in Prostate Cancer

June 22nd 2017

Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation with radical prostatectomy in patients with intermediate-risk prostate cancer.

Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene

June 22nd 2017

Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.

How Urology Clinics of North Texas Is Overcoming Payment Challenges

June 21st 2017

As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.

Recent Patterns Indicate PSA Testing Halt in Decline

June 20th 2017

A recent nationally representative study published in JAMA Internal Medicine found that previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.

Dr. Chi on Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Naive Prostate Cancer

June 20th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

Deeper Understanding Leading to Better Care for Patients With Prostate Cancer

June 17th 2017

Although the past few months have seen several androgen receptor resistance, and described drug approvals for bladder cancer therapies, a wealth of research also is moving the field of prostate cancer forward, since gaining a better understanding of the disease is the best way to find out how to optimally treat—and perhaps ultimately cure—prostate cancer.

Benefit Confirmed for ERBT Plus ADT in Locally Advanced Prostate Cancer

June 14th 2017

The addition of external beam radiation therapy to ADT reduced the risk of disease progression more than 70% compared with ADT alone among patients with locally advanced prostate cancer.

No Mortality Difference Between Prostatectomy, Observation in 20-Year Study

June 14th 2017

Radical prostatectomy does not significantly reduce all-cause or prostate cancer mortality compared with observation through nearly 20 years, according to the results from the phase III PIVOT trial.

PROSPER CRPC Data to Be Released 2 Years Earlier Than Expected

June 13th 2017

Astellas Pharma and Pfizer have announced that phase III results from the PROSPER trial of enzalutamide (Xtandi) in men with nonmetastatic castration-resistant prostate cancer will be ready later this year.

Dr. Loeb on Tests for the Management of Prostate Cancer

June 6th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.

Dr. Feldman on the Significance of Active Surveillance in Prostate Cancer

June 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Dr. Stephenson on 2 Years Following the Management of Localized Prostate Cancer

June 2nd 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

Dr. Abida on the Frequency of Mutations in Prostate Cancer

June 2nd 2017

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the frequency of mutations for patients with prostate cancer.

Dr. Oh on AR-Targeted Therapy and Chemotherapy for CRPC

June 2nd 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Docetaxel Combined With Dexamethasone Shows PSA Response in Patients With CRPC

May 24th 2017

A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high PSA responses compared with previous studies in patients with CRPC.

Guideline Update Clarifies Role of Brachytherapy for Patients With Newly Diagnosed Prostate Cancer

May 24th 2017

The American Society of Clinical Oncology and Cancer Care Ontario have jointly updated their guideline for using brachytherapy treatment for patients with newly diagnosed prostate cancer who require or choose active treatment and are not considering, or are not suitable for, active surveillance.

Dr. Sartor on Sipuleucel-T in mCRPC

May 24th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

AUA Releases Consensus Statements on 3 Main Methods of Prostate MRI, Targeted Biopsy

May 23rd 2017

The American Urological Association, in collaboration with the Society of Abdominal Radiology, convened for a Prostate Cancer Disease Focused Panel to conduct a literature review and create consensus statements regarding the role of prostate magnetic resonance imaging (MRI) and MRI-targeted biopsy in patients with a prior negative biopsy.

Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer Aggressiveness

May 22nd 2017

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.